[{"AccountsPayableCurrent_0_Q1_USD":3127498.0,"ResearchAndDevelopmentExpense_1_Q1_USD":6348668.0,"ShareBasedCompensation_1_Q1_USD":1264424.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q1_pure":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1_Q1_pure":1.016,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1_Q1_pure":0.0188,"Cash_0_Q1_USD":27458423.0,"IncreaseDecreaseInPrepaidExpense_1_Q1_USD":-266026.0,"LeaseAndRentalExpense_1_Q1_USD":50054.0,"PrepaidExpenseCurrent_0_Q1_USD":234972.0,"CurrentIncomeTaxExpenseBenefit_1_Q1_USD":9214.0,"PreferredStockValue_0_Q1_USD":null,"NonoperatingIncomeExpense_1_Q1_USD":1117992.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":820077.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":165891753.0,"StockIssuedDuringPeriodValueAcquisitions_1_Q1_USD":10997952.0,"IncomeTaxesReceivable_0_Q1_USD":3730672.0,"IncreaseDecreaseInIncomeTaxesReceivable_1_Q1_USD":1087927.0,"IncrementalCommonSharesAttributableToCallOptionsAndWarrants_1_Q1_shares":9226266.0,"InterestIncomeExpenseNet_1_Q1_USD":46720.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":1264424.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0_Q1_shares":500000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":53113.0,"PaymentsOfDebtIssuanceCosts_1_Q1_USD":null,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":1264424.0,"PreferredStockSharesAuthorized_0_Q1_shares":10000000.0,"OperatingExpenses_1_Q1_USD":7700703.0,"Assets_0_Q1_USD":31424067.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":27458423.0,"CashAndCashEquivalentsPeriodIncreaseDecrease_1_Q1_USD":5272793.0,"CommonStockSharesIssued_0_Q1_shares":57080356.0,"CommonStockSharesOutstanding_0_Q1_shares":57080356.0,"CommonStockValue_0_Q1_USD":57082.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.12,"GeneralAndAdministrativeExpense_1_Q1_USD":1352035.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-6582711.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":-395834.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.001,"LiabilitiesAndStockholdersEquity_0_Q1_USD":31424067.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":10997952.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-5725159.0,"NetIncomeLoss_1_Q1_USD":-6591925.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":10997952.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-139988685.0,"StockholdersEquity_0_Q1_USD":25960150.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":54773685.0,"AccruedLiabilitiesCurrent_0_Q1_USD":2336419.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommonStockSharesAuthorized_0_Q1_shares":100000000.0,"LiabilitiesCurrent_0_Q1_USD":5463917.0,"ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1_Q1_USD":943215.0,"Ticker":"AVXL","CIK":"1314052","name":"ANAVEX LIFE SCIENCES CORP.","OfficialName":"Anavex Life Sciences Corp. Common Stock","form":"10-Q","period":"20191231","fy":"2020.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"825317693.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Commercial Physical & Biological Resarch","Market":"NASDAQ","SP500":"nan","filed":"20200206"}]